PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Wells Fargo & Company from $56.00 to $68.00. They now have an "overweight" rating on the stock.
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Robert W. Baird from $48.00 to $52.00. They now have an "outperform" rating on the stock.MarketBeat
- PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 MillionPR Newswire
- PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS PatientsPR Newswire
PTCT
Earnings
- 11/7/24 - Beat
PTCT
Sec Filings
- 11/27/24 - Form 8-K
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- PTCT's page on the SEC website